Klineo raises €2m to speed up access to cancer trials
Paris-based Klineo SAS has raised €2M to speed up access to clinical trials for oncology patients using an AI platform.<br />`<br /><br />
Locate Bio Ltd raises £9.2m venture capital
University Nottingham spin out Locate Bio Ltd has added £9.2m venture financing led by Mercia Ventures and Business Growth Fund to its £16.2m raised before.
Electrochaea sells biomethane reactor to Again A/S
Archaeal Power-to-biomethan producer Electrochaea GmbH has sold a BioCat bioreactor to the Danish CCU specialist Again A/S.
Flindr Therapeutics BV secures €20m Series A financing
Oss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.
Nordic Bioproducts Group opens its first production facility
Finnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology
Swiss Biotech Report reporting record turnover
The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn.<span style="mso-ansi-language:EN-US" lang="EN-US"> Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and […]
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Ipsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.
SeaBeLife to use €1.5m award for drug development
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
SeaBeLifeSeabelife SAS to develop next-gen dry AMD drug
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
Seabelife SAS to develop next-gen dry AMD drug
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.